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Abstract
Common variant genome-wide association studies (GWASs) have, to date, identified >24 risk loci 
for Parkinson’s disease (PD). To discover additional loci, we carried out a GWAS comparing 
6,476 PD cases with 302,042 controls, followed by a meta-analysis with a recent study of over 
13,000 PD cases and 95,000 controls at 9,830 overlapping variants. We then tested 35 loci (P < 1 × 
10−6) in a replication cohort of 5,851 cases and 5,866 controls. We identified 17 novel risk loci (P 
< 5 × 10−8) in a joint analysis of 26,035 cases and 403,190 controls. We used a neurocentric 
strategy to assign candidate risk genes to the loci. We identified protein-altering or cis–expression 
quantitative trait locus (cis-eQTL) variants in linkage disequilibrium with the index variant in 29 
of the 41 PD loci. These results indicate a key role for autophagy and lysosomal biology in PD 
risk, and suggest potential new drug targets for PD.
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PD is the second most common neurodegenerative disorder1,2, with a prevalence of 3–4% in 
individuals over 80 years of age3. PD is characterized by the loss of dopaminergic neurons 
in the substantia nigra and the presence of Lewy bodies1,2. These neuropathologies manifest 
in affected individuals primarily as motor-related symptoms, but the involvement of other 
brain regions can lead to nonmotor symptoms4.
Early-onset, familial PD (onset at <60 years of age) accounts for a small fraction of cases5, 
but the identified associated genes, including LRRK2, GBA, and SNCA, provide insight into 
disease pathogenesis6,7. For the later-onset, common form of PD, at least 24 loci have been 
associated at a genome-wide significant level with disease risk in individuals of European 
ancestry8. The narrow-sense heritability (h2) explained by the confirmed PD risk loci is low 
(0.033)9; however, the heritability explained by common variants is estimated at 0.227 (s.d.: 
0.08)9, which suggests that additional loci with smaller effect sizes remain to be discovered.
We carried out a GWAS of 6,476 subjects from a 23andMe PD cohort (PDWBS (Web-Based 
Study of Parkinson’s Disease)) and 302,042 controls genotyped on custom Illumina arrays 
(Fig. 1). The 6,476 PD cases of European ancestry were independent from those previously 
reported8 but met the same inclusion criteria, except that carriers of the LRRK2 G2019S 
mutation were not removed8,10. The 302,042 controls did not report having PD and were of 
similar ancestry as the cases. The data were imputed with Minimac2 using 1000 Genomes 
phase 1 haplotypes11,12. Single-nucleotide polymorphisms (SNPs) with low imputation 
quality or that failed general quality control metrics were removed (Online Methods). After 
correcting for age, sex, and the top principal components (Online Methods), we observed 
minimal inflation for P values genome-wide (λgc = 1.057; λ1000 = 1.004; Supplementary 
Fig. 1).
A total of 12 loci had P < 5 × 10−8 in the PDWBS analysis, including 11 of the loci that 
were reported in a previous GWAS in individuals of European ancestry8 (Table 1). For the 
remaining 13 previously reported loci, we observed P < 0.05 for 11 loci, with no significant 
evidence for association observed in the PDWBS sample for CHMP2B (rs115185635) or 
TMEM229B (rs155399). The remaining novel locus in the PDWBS analysis, rs9468199 (P 
= 1.77 × 10−9), is more than 4 Mb from the nearest PD association in the HLA class II 
region and is independent of rs9275326 (Pconditional = 2.64 × 10−9).
Using genome-wide summary statistics from the PDWBS analysis, we estimated the h2 
value for PD explained by common variants as 0.209 (95% confidence interval (CI): 0.148–
0.271, assuming a prevalence of 0.01), which is similar to the h2 value reported 
previously9,10. Regions contributing to PD heritability were significantly enriched for 
acetylation of histone H3 at lysine 27 (P = 0.001; Supplementary Table 1), a mark of active 
regulatory regions. PD heritability was also enriched for histone marks in central nervous 
system, adrenal, and pancreatic cell types (Supplementary Table 2), in agreement with a 
previous study13.
We next carried out a meta-analysis between the PDWBS GWAS and results for the top 
10,000 variants available from a large-scale meta-analysis for PD with over 13,000 cases and 
95,000 controls8 (PDGene) (Fig. 1). For the 9,830 overlapping SNPs between the PDWBS 
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and PDGene studies, we used an inverse-variance weighted method to combine association 
statistics for meta-analysis14. The odds ratios and P values for the 9,830 overlapping SNPs 
in the PDWBS and PDGene studies were correlated (ρ
−log10(P value) = 0.85, ρOR = 0.58). 
Furthermore, quantile–quantile (Q-Q) plots indicated an increase in the number of variants 
with low P values (Supplementary Fig. 1), even after the exclusion of variants in regions 
previously reported as associated with PD risk at a genome-wide significant level 
(Supplementary Table 3).
The meta-analysis identified 35 loci associated at P < 1 × 10−6, including 15 loci with P < 5 
× 10−8 (Fig. 2, Supplementary Figs. 2 and 3, Supplementary Table 4). Only two of the 
previously reported loci (BCKDK:rs14235 and MAPT:rs17649553) and 2 of the 20 
suggestive loci (FCGR2A:rs4657041, ITGA2B:rs5910) were in linkage disequilibrium (LD) 
(r2 > 0.8) with variants associated (at P < 5 × 10−8) with any phenotype in the NHGRI 
GWAS catalog15. Significant pleiotropy of PD risk loci with other complex diseases has not 
been identified16, but this pleiotropy landscape may change as more modest effects are 
uncovered.
We next sought validation of these 35 candidate loci in an independent cohort of 5,851 cases 
and 5,866 controls of European ancestry genotyped with the semi-customized NeuroX 
Illumina array8,17 (Fig. 1). Twenty-nine of the 35 loci either were directly genotyped on the 
NeuroX array or had suitable proxies (r2 > 0.9 with the original SNP; Supplementary Table 
5). Weaker proxies at four additional SNPs (r2 > 0.5) were available but were not used for 
validation in this study (Supplementary Table 5). In a replication-phase joint analysis of 
these 29 loci (meta-analysis of PDGene, PDWBS, and NeuroX), 16 had P < 5 × 10−8 (Table 
2). Of these 16, all but 3 (rs4073221, rs10906923, and rs9468199) were also nominally 
associated in the NeuroX study (one-sided P < 0.05). A genetic risk score8,18,19 defined by 
these 16 loci, in addition to the previously reported loci, had a non-negligible ability to 
predict PD case status (area under the curve, 0.6518; 95% CI, 0.6419–0.6616). This 
represents a significant improvement over the predictive power of risk scores defined by 
previously reported loci alone (P = 6 × 10−8) (Supplementary Note 1). In sum, we identified 
16 independent PD risk loci with a joint P < 5 × 10−8 and 1 locus (rs601999) with P < 5 × 
10−8 in the discovery cohort with no suitable proxy for replication in the NeuroX cohort 
(Table 2).
Overall, 11 of 17 novel loci were in high LD (r2 > 0.8) with at least one variant predicted to 
affect transcription factor binding (Supplementary Table 6). Of the 17 novel loci and 24 
previously reported loci, 10 contained residual associations with P < 1 × 10−3 after 
conditioning on each region’s most significant SNP in the PDWBS data (Supplementary 
Table 7). These regions included three of the four independent secondary signals reported by 
Nalls et al.8, as well as one variant previously reported at a non-genome-wide significant 
level (P = 5.15 × 10−7)20.
We note that the HLA region association with PD is particularly complex. Two candidate 
genes from the HLA region were nominated on the basis of support from either a protein-
coding variant or an eQTL (Fig. 3). This is in line with a previous study that suggested that 
the PD association in the HLA region may point to multiple HLA factors, including 
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independent regulatory factors21. The association pattern observed at this locus may be 
reminiscent of the HLA association observed in schizophrenia and linked to C4 copy 
number22.
The identification of the causal variants and genes underlying regions associated with 
common, complex disease is a major challenge23. Several statistical methods have been 
proposed for the fine-mapping of causal variants23–25. Alternatively, some studies have 
narrowed down lists of candidate genes by combining multiple levels of evidence with 
scoring-based strategies26,27. Here we implemented a neurocentric strategy to nominate 
candidate genes for PD-associated loci.
We incorporated seven sources of data to annotate the index variant and linked variants from 
PD-associated loci (including eQTLs and expression data from GTEx28, as well as 
expression data from brain cell types in mice29; a full list is provided in the Online 
Methods). We used a two-stage approach to assign candidate genes to each locus (see the 
Online Methods for further details, and Supplementary Fig. 4 for a graphical visualization). 
In the first stage, we assigned a gene to a locus if (i) the index SNP or linked variants (r2 > 
0.6) altered the protein sequence or (ii) the index variant was a cis-eQTL for the gene. When 
no candidate genes were identified by the first stage, we ranked neighboring gene(s) on the 
basis of neurologically related phenotypes and expression and assigned the gene with the 
highest score to the locus (Online Methods).
With this strategy we identified a single candidate gene for 28 loci, and multiple candidate 
genes with similar levels of supporting evidence for 13 loci (Fig. 3, Supplementary Figs. 5 
and 6). The candidate-gene nomination strategy confirmed several known PD risk genes, 
including GBA, LRRK2, SNCA, and MAPT. Among the 41 PD risk loci, a total of 29 loci 
(71%) had either a protein-altering or a cis-eQTL variant linked to the index SNP 
(Supplementary Tables 8 and 9). In addition, we carried out a colocalization analysis to 
determine whether the GWAS signal and the eQTL signal pointed to the same causal 
variant30 (Supplementary Note 1). Seven candidate genes also had evidence for protein–
protein interaction (Online Methods, Supplementary Table 10). Further studies are needed to 
experimentally determine the causal genes in the PD risk loci; however, the identification of 
candidate genes provides testable hypotheses for functional studies.
To gain insight into the biology, we tested the identified candidate genes in the 41 PD risk 
loci for association with any pathways or gene sets compared with a background gene list 
(Online Methods). We investigated whether candidate genes were enriched for pathways 
previously implicated in PD: autophagy, lysosomal, and mitochondrial biology1. PD-
associated signals were enriched (at a threshold of P < 0.05/3 = 0.017) for lysosomal and 
autophagy genes (P = 3.35 × 10−6 and P = 5.71 × 10−3, respectively). The addition of 
candidate genes more than doubled the number of lysosomal genes observed in PD loci and 
improved the enrichment significance (Pall_loci = 3.35 × 10−6, Pnovel_loci = 3.64 × 10−5). We 
also observed that one previously identified gene (MCCC1) and two novel candidate genes 
(COQ7 and ALAS1) mapped to the mitochondrial gene set (Supplementary Table 11).
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Lysosomal biology and its role in the degradation of protein aggregates emerged as a highly 
significant pathway in PD risk. Among the five candidate genes linked to lysosomal biology, 
two were previously identified candidate genes (GBA (glucocerebrosidase) and TMEM175 
(transmembrane protein 175)), and three were newly identified candidate genes (CTSB 
(cathepsin B), ATP6V0A1 (ATPase H+ transporting V0 subunit a1), and GALC 
(galactosylceramidase)). Glucocerebrosidase is required for normal lysosomal activity and 
α-synuclein degradation. In addition, GBA loss-of-function alleles are a common PD risk 
factor31. TMEM175 was recently shown to encode a potassium channel that can regulate 
lysosomal function32, and the missense variant TMEM175 M393T is strongly linked to the 
index variant in the region (Supplementary Table 8). CTSB is a lysosomal cysteine protease. 
A PD risk allele is linked to a cis-eQTL for CTSB in multiple tissues (Supplementary Table 
9), where the risk allele is associated with reduced levels of CTSB mRNA. Double-knockout 
mice for Ctsb and Ctsl (cathepsin L) show a tremor phenotype with cerebral and cerebellar 
atrophy33. CTSB is also capable of degrading membrane-bound and soluble α-synuclein in 
mice34.
Autophagy is the catabolic process that targets long-lived proteins and dysfunctional 
organelles for lysosomal degradation. Autophagy and lysosomal degradation have been 
implicated in PD by rare familial and common GWAS-associated GBA variants. We note 
that a strong cis-eQTL for lysine acetyltransferase 8 (KAT8) is associated with PD risk, with 
lower levels of KAT8 mRNA linked to increased PD risk. Inhibition of KAT8 was recently 
shown to decrease autophagic flux35.
Next, we used INRICH36 to investigate whether PD-associated regions were enriched for 
gene sets in an unbiased fashion. Once again, we found significant enrichment of the 
lysosomal pathway (Padjusted = 0.02) (Supplementary Table 12). We further examined the 
expression of the PD candidate genes in a brain-specific cell-type expression data set in 
mice29; however, we observed broad expression across the major brain cell types, and no 
clear cell-type-specific pattern was evident (Supplementary Fig. 7).
Among the candidate genes newly identified in this study is SH3GL2 (SH3 domain-
containing GRB2-like 2, endophilin A1), a gene recently demonstrated to be phosphorylated 
by LRRK2 and which may have a role in clathrin-mediated endocytosis of synaptic 
vesicles37. Dysregulation of Elovl7 (elongation of very long chain fatty acids protein 7) in 
mice results in several neurological phenotypes, including inflammatory astrocytosis and 
microgliosis in the brain, and neuronal degeneration38. Upregulation of the candidate gene 
SCN3A (sodium voltage-gated channel α-subunit 3) enhances neuronal excitability and is 
associated with epilepsy in both humans and animal models39.
The new loci also encode three transcription factors: SATB1, ZNF184, and TOX3. TOX3 
has been implicated in neuronal survival40, and SATB1 has been associated with T cell 
function, particularly the development of regulatory T cells41.
Several of the PD candidate genes are within the ‘druggable’ genome42, including the 
previously identified serine/threonine kinase 39 (STK39) and the novel candidate gene 
inositol 1,4,5-trisphosphate kinase B (ITPKB). An in-frame deletion of ITPKB 
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(rs147889095) is linked to a PD-associated variant, and complete loss of ITPKB was 
reported in a patient with common-variable immunodeficiency43. STK39 is a kinase linked 
to hypertension44, regulation of K+ levels, and the cellular stress response.
In summary, this study presents what to our knowledge is the largest meta-analysis of PD so 
far, involving a total of 26,035 cases and 403,190 controls. We identified 17 novel PD loci 
and, using a neurocentric candidate-gene nomination pipeline, found that several of the 
newly identified PD risk genes have a role in lysosomal biology and autophagy. The 
identification of these candidate genes allows for the prioritization of functional studies to 
determine causal genes for PD and possible therapeutic targets.
ONLINE METHODS
PDWBS GWAS
The PDWBS is a genome-wide analysis of 6,476 PD cases and 302,042 control subjects, all 
of whom were customers of 23andMe Inc. and consented to participate in research. The 
study protocol was approved by the external AAHRPP-accredited institutional review board, 
Ethical and Independent Review Services (E&I Review). Cases and controls were 
designated on the basis of surveys10. Controls were selected from 23andMe Inc. research 
participants who did not self-report as having been diagnosed with PD. Although the use of 
self-reported controls can result in a reduction of power, the effect of this on the current 
study was probably minimal (Supplementary Note 1). Any samples present in the PDGene 
study8 were removed from the PDWBS analysis. The average age of cases and controls was 
67.6 and 50.8 years, respectively. The study also included 147 cases (2.3%) and 554 controls 
(0.18%) that were LRRK2 G2019S carriers. Removing LRRK2 G2019S carriers from the 
analysis removed genome-wide significant associations at the LRRK2 locus.
DNA extraction and genotyping were performed on saliva samples by CLIA-certified CAP-
accredited clinical laboratories of the Laboratory Corporation of America. Samples were 
genotyped on one of the following four platforms: V1 and V2, two variants of the Illumina 
HumanHap550+ BeadChip, with ~25,000 custom SNPs and ~950,000 total SNPs; V3, 
Illumina OmniExpress+BeadChip with custom SNPs to increase overlap with the V2 chip, 
with a total of ~950,000 SNPs; and V4, a custom chip that included SNPs overlapping V2 
and V3 chips, low-frequency coding variants and ~570,000 SNPs. Samples with a call rate 
lower than 98.5% were reanalyzed, and research participants with samples that failed 
repeatedly were re-contacted and asked to provide additional samples.
Research participants were restricted to those of mainly (>97%) European ancestry10,45. All 
research participants in the study were also required to share <700 cM identity by descent 
(IBD) (estimated by a segmental IBD estimation algorithm46), corresponding approximately 
to the sharing expected between first cousins. We additionally excluded individuals who 
shared >700 cM IBD with any 23andMe research participant whose data was used in the 
PDGene GWAS. Data were imputed on 1000 Genomes phase 1 haplotypes (September 2013 
release) with Minimac2 on default settings11,47. Imputation was run separately on data from 
each genotyping platform.
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For genotyped SNPs, SNPs were removed if they were genotyped on only the V1 and/or the 
V2 chip, if they failed a parent–offspring transmission test on trio data, if they were not in 
Hardy–Weinberg equilibrium (P < 10−20), or if they had a call rate < 0.90. For imputed 
SNPs, SNPs were removed if they had an average r2 < 0.5 or minimum r2 < 0.3 in any 
imputation batch, or failed a test for imputation batch effect (testing imputation dosage with 
imputation batch; P < 10−50).
We applied logistic regression assuming an additive model to test for association between 
case/control status and either genotypes or imputed dosages (for imputed SNPs). Only SNPs 
with minor allele frequency (MAF) > 0.1% were analyzed. Covariates were added to adjust 
for age, sex, the first five principal components, and genotyping platform version. A total of 
12,896,220 variants (11,933,700 SNPs) were analyzed. The genomic inflation factor was 
calculated from the median P value of analyzed variants. Scaling of the genomic inflation 
factor by sample size was carried out as described previously for 1,000 cases and 1,000 
controls48.
Meta-analysis of PD GWASs
Summary odds ratios, 95% CIs, and P values of the 10,000 most significant GWAS meta-
analysis results were obtained from PDGene (“URLs”). Cohort descriptions, quality control, 
and meta-analysis for this study have been described previously8. SNP s.e. was derived from 
the reported P values and odds ratios. More specifically, the z-statistic was calculated as the 
square root of the inverse χ-square transformation of the P value, and the s.e. was calculated 
as follows: s.e.m. = ln(odds ratio)/absolute(z-score).
There were 9,830 SNPs in common between the PDGene and the PDWBS data sets. A 
fixed-effects model based on inverse-variance weighting, as implemented in METAL, was 
used to combine summary statistics from the two studies14. Heterogeneity values (I2 and Q) 
were obtained with PLINK49. Novel signals of association were defined as genome-wide 
significant associations in the meta-analysis that did not overlap loci associated with PD at 
genome-wide significant thresholds in the PDGene data (35 loci with P < 1 × 10−6).
Joint analysis with NeuroX
The NeuroX cohort was previously described8,17. Briefly, 5,851 cases and 5,866 controls of 
European ancestry were genotyped on a semi-custom NeuroX array. A logistic regression 
was carried out to test for association, with covariates to adjust for age, sex, and population 
ancestry (the first five principal components). Twenty-five of the 35 novel loci were directly 
genotyped on the chip, and four additional SNPs had suitable proxies (r2 > 0.9). At these 29 
SNPs, we carried out a fixed-effects inverse-variance weighted meta-analysis14 for all three 
studies (PDGene, PDWBS, and NeuroX) as described above.
Conditional analysis
Conditional analysis was run on all 17 loci that were significantly associated with PD in the 
joint meta-analysis (P < 5 × 10−8) and the 24 previously reported PD loci using the PDWBS 
study. For each locus, SNPs within 500 kb of the index SNP (the SNP with the most 
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significant P value) were tested for association by the same methods as described above for 
the PDWBS GWAS with the index SNP added as an additional covariate.
Heritability estimates
We used LD score regression (LDSC)50,51 to compute the narrow-sense heritability (h2) 
estimates of PD in the PDWBS GWAS data (described above). Several methods exist for 
estimating h2 with GWAS data50–52. We used LDSC to estimate h2 in this study because it 
requires only summary-level data and is more computationally efficient for larger data sets. 
Reference LD scores were computed with the European ancestry subset of the 1000 
Genomes data for SNPs within 500 kb of the SNP to be scored. Strict filtering was applied 
to ensure the robustness of heritability estimates as recommended50,51. After filtering, Z-
scores for 7,629,099 SNPs from the 23andMe study were used as input to LDSC. We further 
used the stratified LD-score regression approach to partition heritability into 24 different 
cell-type-agnostic annotation categories including conserved regions, histone marks, DNase 
I hypersensitivity sites, ENCODE chromatin states, and enhancers51, as well as 10 different 
cell-type-specific histone annotations. Significant enrichment was assessed at a strict 
Bonferroni threshold of 0.0021 (0.05/24) for the 24 general categories, and 0.005 for the 
cell-type-specific enrichment.
Pleiotropy analysis: overlap with EBI-NHGRI GWAS catalog
Data were downloaded from the EBI-NHGRI catalog15 (version available on 17 April 
2016). If a variant in the meta-analysis was within 500 kb and in LD (r2 > 0.8) with an 
association (P < 5 × 10−8) in the catalog, the meta-analysis signal was considered to be 
overlapping the reported signal.
A neurocentric strategy to identify candidate causal variants and genes
Associated index SNPs were paired to candidate genes on the basis of two broad levels of 
evidence: variant-level support and gene-level support (see Supplementary Fig. 4 for a 
graphic representation). In the former category, index SNPs were paired with candidate 
genes if there was evidence that the index SNP or an SNP in LD (r2 > 0.6) with the index 
SNP was annotated with a putative high-impact variant (chromosome number variation, 
exon loss variant, frame-shift variant, rare amino acid variant, splice donor or acceptor 
variant, start-lost, stop-gained or stop-lost, and transcript ablation) or moderate-impact 
variant (3′ or 5′ UTR truncation and exon loss, coding sequence variant, disruptive in-
frame deletion or insertion, in-frame deletion or insertion, missense variant, regulatory 
region ablation, splice region variant, and transcription factor binding-site ablation). We 
obtained variant annotations by running SnpEff53 on dbSNP build 142. A second source of 
variant-level support consisted of cis-eQTL evidence. Cis-eQTLs as pre-computed by GTEx 
(v6)28 were downloaded directly from the GTEx portal (“URLs”). Although eQTL results 
were available for 46 tissues, including ten regions from the brain, our search for eQTLs was 
limited by the sampled tissues and cell types, and therefore we might have missed any 
eQTLs that are cell-type or tissue specific, in addition to eQTLs that are present only under 
certain stimuli (for example, ‘response’ eQTLs). The index SNP was tested for significant 
association with any gene where the TSS was within 250 kb of the index SNP. As roughly 
90% of eQTLs are within 250 kb of a gene28, it is likely that we captured the majority of 
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eQTLs while missing rarer, more distal events. For brain eQTLs, a strict Bonferroni 
correction was applied to the raw eQTL P values to adjust for multiple testing of genes 
within 250 kb of the index SNP. For other tissues, only eQTLs with a false discovery rate of 
<0.05 as determined by GTEx28 were considered. We weighted brain and non-brain eQTLs 
equally.
Gene-level support was used when an index SNP had no candidate genes supported by 
variant-level data as described above. A list of genes within 250 kb of the index SNP was 
obtained (gene models used by GTEx were downloaded from the GTEx portal), and each 
gene was scored for neurological relevant features or annotations. Genes were first weighted 
for neurological relevant phenotypic annotations. Genes were (i) scored for being 
differentially expressed between PD patients and healthy controls (see Supplementary Note 
1 for further details) (311 genes total genome-wide); (ii) annotated with ‘neuro’-associated 
phenotypes in FlyBase54 (1,521 genes); (iii) scored for behavioral, neurological, and 
olfactory phenotypes annotated in MGI55 (3,890 genes); and (iv) annotated with any 
phenotypes related to neurological disorders or the brain in OMIM56 (521 genes). Lastly, 
genes were scored for being expressed (median expression across samples > 2 reads per 
kilobase per million mapped reads) in any cohort of GTEx brain region samples (15,197 
genes) or in at least one brain cell type in the mouse expression data set29 (astrocyte, 
microglia, neuron, or oligodendrocyte) (12,092 genes). For the gene-level support, we used a 
tiered scoring scheme to weight phenotypic annotations more heavily than expression in the 
brain (scores demarked in Supplementary Fig. 4) to enrich for genes with demonstrated 
neurological related roles. At each locus, the gene (or tied genes) with the highest score was 
nominated as the candidate gene for the region.
Protein–protein and coexpression analysis
All protein-coding genes within 250 kb of PD-associated loci (Supplementary Table 13) 
were used as input to STRING57. Gene pairs that were either coexpressed or involved in 
experimentally validated protein–protein interactions with a medium score or higher (score ≥ 
0.4) are reported in Supplementary Table 10.
Pathway enrichment analysis
Previously reported PD loci and novel PD associations were tested for enrichment in 
particular pathways or gene sets. First, the nominated candidate genes for these PD-
associated loci were tested for enrichment in several targeted gene sets by a hypergeometric 
test. The background list of genes for comparison was matched to the neurological-centric 
candidate-gene nomination pipeline. The background list thus consisted of genes that had 
mouse knockout phenotypes, had fly mutant phenotypes, had OMIM-related phenotype 
annotations, had nominally significant cis-eQTLs in GTEx, were differentially expressed in 
PD patients versus controls, and were expressed in GTEx brain tissue or mouse brain cell 
types in the Barres data set.
We obtained mitochondrial genes from MitoMiner58 using the MitoCarta59,60 reference set 
after excluding genes that mapped to the mitochondria (genes that map to the mitochondria 
were not included in this metaanalysis). Lysosomal genes were obtained from the hlGDB61 
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using only the proteomics and literature resources. Finally, we obtained autophagy genes 
from the Human Autophagy Database62, as well as ten additional genes reported in a recent 
siRNA screen of autophagic flux modulators35. A list of all genes in each pathway is 
provided in Supplementary Note 1. The minimum P value per gene (for genes that an SNP 
within the 9,830 variants assayed in this meta-analysis mapped to) is provided in 
Supplementary Tables 14–16.
Second, we applied a non-targeted gene-set enrichment approach using INRICH36 to assess 
whether regions associated with PD were enriched for genes in KEGG63 and Gene Ontology 
(GO)64 gene sets. The 24 previously reported PD index variants and the 17 novel PD-
associated variants reported in this study were used as input into PLINK’s65 “show-tags” 
function. The European 1000 Genomes12 samples were used for reference LD patterns. An 
interval for each PD-associated variant was defined as the region from the leftmost tag 
variant to the rightmost tag variant in the 1000 Genomes data.
We ran INRICH on these 41 intervals with the default settings, with the exception of 
increasing the number of replicates and bootstraps to 5,000 (-r 5000 --q 5000) and setting 
the pre-compute feature to false for software stability (-c). Enrichment for KEGG and GO 
gene sets was assessed separately.
Data availability
A Life Sciences Reporting Summary for this paper is available. Summary statistics for the 
9,830 variants presented in the discovery phase meta-analysis are available at http://research-
pub.gene.com/chang_et_al_2017. The full GWAS summary statistics for PDWBS will be 
made available through 23andMe and Genentech to qualified researchers under an 
agreement with 23andMe that protects the privacy of the 23andMe participants and an 
agreement with Genentech for data sharing. Please contact D.H. (dhinds23andme.com) for 
more information and to apply to access the data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
A flow chart of the two-stage meta-analysis design. In stage 1, we carried out a meta-
analysis of 9,830 SNPs between the PDWBS and PDGene studies. Thirty-five loci with P < 
1 × 10−6 were carried forward into the replication-phase meta-analysis. In stage 2, we 
carried out a meta-analysis between the two discovery-phase studies and the NeuroX study 
for these 35 loci. Of these loci, 16 of the 29 available in NeuroX and 1 locus without 
replication data were carried forward for downstream analyses (see the main text for further 
details).
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Figure 2. 
Results of the Parkinson’s disease discovery-phase meta-analysis. The top SNPs in 
associated regions are indicated by pink symbols. Candidate genes for previously associated 
loci are labeled in black (P < 5 × 10−8 in the discovery phase) or gray text (P > 5 × 10−8 in 
the discovery phase); candidate genes for newly identified loci are labeled in red. The y-axis 
shows the two-sided unadjusted −log10(P) values for association with PD. SNPs with P < 1 
× 10−25 are indicated by triangles.
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Figure 3. 
The candidate genes for regions associated with Parkinson’s disease. The most likely 
candidate gene is annotated for each region that was significantly associated with PD in the 
final joint analysis. Black or gray text indicates previously reported loci that had P values 
less than or greater than 5 × 10−8 in the discovery phase, respectively. Red text indicates 
newly identified loci that were significantly associated with PD in the final joint analysis. 
Gray lines at the outer edge spanning multiple genes indicate candidate genes within a single 
locus. Chromosome numbers are shown in the gray shaded ring, and support for candidate 
genes is indicated by color-coding in the inner rings. The innermost ring indicates 
expression of the gene in brain cell types (in a mouse expression data set) or in human brain 
regions (in GTEx), or differential expression between PD brains and healthy control brains.
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